AVEO Pharmaceuticals, Inc.

NasdaqCM:AVEO Stock Report

Market Cap: US$521.4m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

AVEO Pharmaceuticals Future Growth

Future criteria checks 5/6

Key information

123.0%

Earnings growth rate

122.84%

EPS growth rate

Biotechs earnings growth23.0%
Revenue growth rate36.2%
Future return on equityn/a
Analyst coverage

Low

Last updatedn/a

Recent future growth updates

Recent updates

AVEO Oncology shares jumped on acqusition by LG Chem for $15.00 per share in cash

Oct 18

Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money

Oct 04
Here's Why AVEO Pharmaceuticals (NASDAQ:AVEO) Can Manage Its Debt Despite Losing Money

A Current Assessment On AVEO Pharmaceuticals

Aug 15

Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt

Jun 21
Rock star Growth Puts AVEO Pharmaceuticals (NASDAQ:AVEO) In A Position To Use Debt

AVEO Pharmaceuticals Is Primed For A Breakout

May 24

Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results

Mar 17
Here's What Analysts Are Forecasting For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) After Its Annual Results

AVEO Pharmaceuticals: Finally Ready To Reboot

Mar 09

AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Mar 03
AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Nov 23
AVEO Pharmaceuticals (NASDAQ:AVEO) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

AVEO Pharmaceuticals: Sticking To The Plan

Oct 29

AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment

Jul 24

Earnings and Revenue Growth Forecasts

NasdaqCM:AVEO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202421448N/AN/A1
12/31/202316212N/AN/A1
12/31/2022110-24N/AN/A1
9/30/202294-29-23-23N/A
6/30/202279-36-31-31N/A
3/31/202261-41-47-47N/A
12/31/202142-53-57-57N/A
9/30/202126-58-58-58N/A
6/30/202114-56-56-56N/A
3/31/20217-49-45-45N/A
12/31/20206-36-38-38N/A
9/30/20206-29-33-32N/A
6/30/202028-4-8-8N/A
3/31/2020280-6-6N/A
12/31/2019299-3-3N/A
9/30/20193036-2-2N/A
6/30/20196-3-24-24N/A
3/31/201964-27-27N/A
12/31/20185-5-25-25N/A
9/30/20184-24-22-22N/A
6/30/20186-28-22-22N/A
3/31/20186-65-20-20N/A
12/31/20178-65-19-19N/A
9/30/20178-74-23-23N/A
6/30/20174-53-29-29N/A
3/31/20174-28-26-26N/A
12/31/20163-27-31-31N/A
9/30/20166-28-24-24N/A
6/30/201620-15N/A-6N/A
3/31/201620-12N/A-13N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: AVEO is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).

Earnings vs Market: AVEO is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: AVEO is expected to become profitable in the next 3 years.

Revenue vs Market: AVEO's revenue (36.2% per year) is forecast to grow faster than the US market (6.9% per year).

High Growth Revenue: AVEO's revenue (36.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if AVEO's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/01/21 21:36
End of Day Share Price 2023/01/19 00:00
Earnings2022/09/30
Annual Earnings2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AVEO Pharmaceuticals, Inc. is covered by 15 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
James BirchenoughBMO Capital Markets Equity Research
Madhu KumarB. Riley Securities, Inc.